Ixoberogene soroparvovec is under clinical development by Adverum Biotechnologies and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ixoberogene soroparvovec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ixoberogene soroparvovec overview

ADVM-022 is under development for the treatment of wet age-related macular degeneration (wAMD, wet exudative macular degeneration). The drug candidate is a vector based anti-VEGF cDNA administered through intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). It is developed based on next generation adeno-associated virus (AAV)-based directed evolution platform. It was under development for the treatment of diabetic retinopathy including diabetic macular edema.

Adverum Biotechnologies overview

Adverum Biotechnologies (Adverum), formerly Avalanche Biotechnologies, is a clinical-stage gene therapy provider. The company’s product pipeline includes ADVM-022 for Wet AMD and ADVM-022 for DME. Its products are used for the treatment of unmet medical needs in ocular and rare diseases. Adverum’s ADVM-022 is a single, in-office intravitreal (“IVT”) injection gene therapy that improves the real-world vision outcomes for patients. The company collaborates with academic institutions and pharmaceutical companies. It also offers research and development, pre-clinical services, and manufacturing services. The company operates in the US, the UK, and France. Adverum is headquartered in Redwood City, California, the US.

For a complete picture of Ixoberogene soroparvovec’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.